MétaCan
← tous les travaux

New molecular assays for cancer diagnosis and targeted therapy.

2008· article· en· 8 citations· W2397537490 sur OpenAlex

Pourquoi ce travail est-il dans la base ?

Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.

Affiliation canadienneUne personne signataire a déclaré un établissement canadien. C'est la seule voie dont dispose la base habituelle.

Le tri à trois modèles

les 1 000 travaux triés →

Les trois modèles l'ont jugé hors champ.

strate : aff_core · poids de sondage : 5595.24 (l'échantillon est stratifié ; tout taux calculé sans le poids est faux)
Claude Opus 4.8OUT
genre : other
porte sur le Canada: non
confiance: high

Review of molecular assays for cancer diagnosis and targeted therapy; the object is diagnostic technology and its clinical regulation.

GPT-5.6 (high)OUT
genre : conceptual
porte sur le Canada: non
confiance: high

The review concerns cancer diagnostic assays and treatments, not research methodology.

Grok 4.5OUT
genre : other
porte sur le Canada: non
confiance: high

Industry-oriented review of molecular diagnostic cancer assays and personalized medicine testing.

Résumé

Microarray multiplex protein measurement of biomarker-based molecular diagnostic and prognostic cancer testing assays is destined to become a large growth segment of the immunodiagnostic industry. Assays encompass immunohistochemistry, fluorescence in situ hybridization, ELISA and sequencing methods that must comply with stringent regulatory specifications. Current test services available range from single-site service-based assays to multi-laboratory testing. Some tests have regulatory approval, whereas others are regulated by the Clinical Laboratory Improvement Act or the College of American Pathologists, or both. Expectations of personalized medicine are building, and the future is expected to bring truly targeted treatments based on test results. In this review, biomarkers, screening, diagnosis, potential prognosis and treatment pertaining to colorectal, breast, and lung cancers are discussed and evaluated. Assay data are expected to improve clinical indices and treatment algorithms, leading to dynamic disease models for real-time, data-modulated patient management.

Conservé avec la notice de tri, où il sert de preuve aux étiquettes ci-dessus.

La notice

Revue
PubMed
Thématique
Advanced Biosensing Techniques and Applications
Domaine
Biochemistry, Genetics and Molecular Biology
Établissements canadiens
Cytodiagnostics (Canada)
Organismes subventionnaires
Mots-clés
Companion diagnosticMultiplexMedicineBiomarkerTargeted therapyColorectal cancerOncologyCancerBiomarker discoveryPrecision medicinePersonalized medicineLung cancerDiseaseDiagnostic testBreast cancerInternal medicineBioinformaticsPathologyProteomicsBiologyGene
Résumé présent dans OpenAlex
oui